DETERMINATION OF THE ENANTIOMERS OF THIORIDAZINE, THIORIDAZINE 2-SULFONE, AND OF THE ISOMERIC PAIRS OF THIORIDAZINE 2-SULFOXIDE AND THIORIDAZINE 5-SULFOXIDE IN HUMAN PLASMA

被引:41
作者
EAP, CB
KOEB, L
POWELL, K
BAUMANN, P
机构
[1] Unité de Biochimie, Psychopharmacologie Clinique, Département Universitaire de Psychiatrie Adulte (DUPA), CH-1008 Prilly-Lausanne, Site de Cery
来源
JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS | 1995年 / 669卷 / 02期
关键词
D O I
10.1016/0378-4347(95)00096-2
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Thioridazine is a commonly prescribed phenothiazine drug administered as a racemate and it is believed that its antipsychotic effect is mainly associated with (R)-thioridazine. A method based on high-performance liquid chromatography has been developed for the determination of the enantiomers of thioridazine and thioridazine 2-sulfone (THD 2-SO2 or sulforidazine) and of the enantiomers of the diastereoisomeric pairs of thioridazine 2-sulfoxide (THD 2-SO or mesoridazine) and thioridazine 5-sulfoxide (THD 5-SO) in the plasma of thioridazine-treated patients. The method involves sequential achiral and chiral HPLC. The limits of quantitation for total (R)+(S) concentrations were found to be 15 ng/ml for thioridazine and 5 ng/ml for its metabolites. The limits for the determination of the (R)/(S) ratios were found to be 60 ng/ml for racemic THD and 10 ng/ml for racemic THD 2-SO, THD 2-SO2, THD 5-SO (FE) and THD 5-SO (SE). The method has been used to determine the concentrations of the enantiomers of thioridazine and of its metabolites in the plasma of a patient treated with 100 mg of racemic thioridazine hydrochloride per os per day for 14 days. The results show a high enantioselectivity in the metabolism of this drug: the (R)/(S) ratios for THD, THD 2-SO (FE), THD 2-SO (SE), THD 2-SO2, THD 5-SO (FE) and THD 5-SO (SE) were found to be 3.90, 1.22, 6.10, 4.10, 0.09 and 28.0, respectively.
引用
收藏
页码:271 / 279
页数:9
相关论文
共 17 条
[1]   CLINICAL-SIGNIFICANCE OF THE SPARTEINE-DEBRISOQUINE OXIDATION POLYMORPHISM [J].
BROSEN, K ;
GRAM, LF .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 36 (06) :537-547
[3]   ARTIFACTS IN THE ANALYSIS OF THIORIDAZINE AND OTHER NEUROLEPTICS [J].
EAP, CB ;
KOEB, L ;
BAUMANN, P .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1993, 11 (06) :451-457
[4]   PLASMA-LEVELS OF TRIMIPRAMINE AND METABOLITES IN 4 PATIENTS - DETERMINATION OF THE ENANTIOMER CONCENTRATIONS OF THE HYDROXY METABOLITES [J].
EAP, CB ;
KOEB, L ;
HOLSBOERTRACHSLER, E ;
BAUMANN, P .
THERAPEUTIC DRUG MONITORING, 1992, 14 (05) :380-385
[5]   LIGHT-INDUCED RACEMIZATION - ARTIFACTS IN THE ANALYSIS OF THE DIASTEREOISOMERIC PAIRS OF THIORIDAZINE 5-SULFOXIDE IN THE PLASMA AND URINE OF PATIENTS TREATED WITH THIORIDAZINE [J].
EAP, CB ;
SOUCHE, A ;
KOEB, L ;
BAUMANN, P .
THERAPEUTIC DRUG MONITORING, 1991, 13 (04) :356-362
[6]  
EAP CB, UNPUB
[7]  
EAP CB, 1994, 3RD P INT S CHIR DIS
[8]   THE GENETIC-POLYMORPHISM OF DEBRISOQUINE SPARTEINE METABOLISM - CLINICAL ASPECTS [J].
EICHELBAUM, M ;
GROSS, AS .
PHARMACOLOGY & THERAPEUTICS, 1990, 46 (03) :377-394
[9]  
HEATH A, 1985, VET HUM TOXICOL, V27, P100
[10]   DETERMINATION OF THIORIDAZINE ENANTIOMERS IN HUMAN SERUM BY SEQUENTIAL ACHIRAL AND CHIRAL HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY [J].
JORTANI, SA ;
POKLIS, A .
JOURNAL OF ANALYTICAL TOXICOLOGY, 1993, 17 (06) :374-377